Pfizer Inc. (PFE) is a global biopharmaceutical company, not an ETF. Its analyst coverage is unusually divided. Because Pfizer shares have rallied to a 52-week high around $30, most published price targets now sit at or below the market price. The overall average of verified targets is roughly $29, with a full range of about $25 to $36 — so the "analyst consensus" is effectively neutral to cautious.
Bullish targets, however, do exist. Guggenheim holds a Buy rating with a $31 target, Scotiabank recently raised its target to $33 with a Sector Outperform rating, Argus Research upgraded the stock to Buy in early 2026 with a $35 target, and at least one firm carries a $36 target. Averaging these above-price targets ($31, $33, $35, and $36) yields roughly $33.75, rounded to the $34 central target used throughout this article.
On the cautious side, RBC Capital initiated coverage with an Underperform rating and a $25 target, while Barclays initiated at Underweight with a $25 target. Neutral voices dominate the middle: JPMorgan raised its target to $30 in early October 2026, HSBC lifted its target to $30, and BMO Capital Markets lowered its target to $30 from $34. The reasoning behind the divide is consistent — bulls focus on Pfizer's oncology pipeline and valuation, while skeptics emphasize the revenue that will be lost as key drugs lose patent protection.
Pfizer shares closed near $30.11 in late October 2026, just under their 52-week high of about $30.25, with a 52-week low of $23.62. The stock carries a forward dividend yield near 5.7% and trades at a relatively modest forward P/E (price-to-earnings ratio) against full-year 2026 adjusted EPS (earnings per share) guidance of $2.80 to $3.00.
Reaching $34 from about $30.11 implies an upside of roughly 13% — a substantial move that would take the stock decisively beyond its all-time recent highs. That path would likely require a meaningful re-rating: either stronger-than-expected earnings revisions, clearer proof that new oncology and obesity products can offset looming patent losses, or both. The valuation is already attractive relative to the broader market, but valuation alone has not been enough to lift the stock above its current range in recent years.
The most important technical fact is that Pfizer just set a 52-week high near $30.25, meaning the stock is testing a level it has not cleared before. That breakout area now functions as near-term resistance; a sustained close above roughly $30.25 would mark fresh multi-year highs. On the downside, the $28 to $29 zone — where shares consolidated before the recent advance — represents initial support, with the $25 level, tied to several cautious analyst targets, providing a deeper floor. The stock's low beta (about 0.28) reflects its defensive, dividend-oriented character, which tends to blunt both sharp rallies and steep selloffs.
Analyst price targets typically reflect a roughly 12-month research horizon, though individual firms vary, and no specific horizon is guaranteed. Investors tracking the $34 target should watch Pfizer's next quarterly earnings report (scheduled around early November 2026), any revisions to full-year guidance, obesity and oncology data readouts, updates on the Metsera and Seagen programs, and broader healthcare-sector rotation driven by interest-rate policy. Analyst rating and target changes will also matter, given how closely the stock's range tracks Street expectations.
Tickeron's AI Daily Buy/Sell Signals use artificial intelligence to continuously monitor thousands of stocks and ETFs, generating Buy, Sell, or Hold signals based on shifting market conditions, technical behavior, and AI-driven analysis. The tool is designed to help traders spot emerging opportunities, keep an eye on existing positions, and identify changing trends more efficiently than manual screening. For investors following PFE, pairing these signals with fundamental research can add a timely, data-driven layer to the decision-making process. Explore the AI Daily Buy/Sell Signals to see how it can fit your trading workflow.
Whether PFE can reach $34 depends less on valuation — which already looks modest — and more on whether Pfizer can convincingly demonstrate that its oncology and obesity pipeline can replace revenue lost to patent expirations. The $34 central target, derived from the average of analyst targets above the current price, implies a roughly 13% gain, while the broader analyst average of about $29 and the $25-to-$36 range show how sharply opinions diverge. Strong pipeline execution, disciplined costs, and a supportive rate backdrop could help; continued LOE erosion, pipeline setbacks, or renewed pricing pressure could keep the stock rangebound. Investors should watch earnings, guidance, and clinical data as the decisive inputs, rather than treating any single price target as a certainty.
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
A.I.dvisor indicates that over the last year, PFE has been loosely correlated with BMY. These tickers have moved in lockstep 57% of the time. This A.I.-generated data suggests there is some statistical probability that if PFE jumps, then BMY could also see price increases.
| Ticker / NAME | Correlation To PFE | 1D Price Change % | ||
|---|---|---|---|---|
| PFE | 100% | -0.86% | ||
| BMY - PFE | 57% Loosely correlated | -0.91% | ||
| AMGN - PFE | 52% Loosely correlated | -0.14% | ||
| NVS - PFE | 49% Loosely correlated | +0.19% | ||
| BIIB - PFE | 48% Loosely correlated | -0.87% | ||
| SNY - PFE | 47% Loosely correlated | -1.04% | ||
More | ||||